Moderna (NASDAQ: MRNA) has been one of the most talked-about stocks over the past year. The biotech company became the first to bring a coronavirus vaccine candidate into clinical testing -- and the second to bring a vaccine to market -- and using a new technology, to boot. Let's take a look at the three things about Moderna that the smartest investors know.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting